CIK 0001235912 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
CVRx, Inc.
Sign in to watch- Ticker
- CVRX
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 7634162850
- Business address
- 9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS, MN, 55445
- Former names
- CVRX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-03 | Yared Nadim Chief Executive Officer | Option exercise | +5,916 | $0.24 | $1K | 20,010 |
| 2022-02-03 | Yared Nadim Chief Executive Officer | Option exercise | +1,266 | $0.24 | $300 | 21,276 |
| 2022-02-03 | Yared Nadim Chief Executive Officer | Option exercise · Stock Option (right to buy) | −2,659 | 0 | ||
| 2022-02-03 | Yared Nadim Chief Executive Officer | Option exercise · Stock Option (right to buy) | −5,057 | 0 | ||
| 2022-02-03 | Yared Nadim Chief Executive Officer | Option exercise · Stock Option (right to buy) | −3,792 | 0 | ||
| 2022-02-03 | Yared Nadim Chief Executive Officer | Option exercise · Stock Option (right to buy) | −5,916 | 0 | ||
| 2022-02-03 | Yared Nadim Chief Executive Officer | Option exercise · Common Stock | −1,266 | 11,375 | ||
| 2022-01-19 | Yared Nadim Chief Executive Officer | Gift | −10,500 | 2,586 | ||
| 2022-01-18 | VERRASTRO PAUL Chief Marketing Officer | Grant or award · Stock Option (right to buy) | +41,200 | 41,200 | ||
| 2022-01-18 | OASHEIM JARED Chief Financial Officer | Grant or award · Stock Option (right to buy) | +56,200 | 56,200 | ||
| 2022-01-18 | BRUHN-DING DEAN VP of Reg. Affairs and QA | Grant or award · Stock Option (right to buy) | +23,600 | 23,600 | ||
| 2022-01-18 | Galle Liz VP of Global Clinical Research | Grant or award · Stock Option (right to buy) | +25,900 | 25,900 | ||
| 2022-01-18 | Yared Nadim Chief Executive Officer | Grant or award · Stock Option (right to buy) | +186,400 | 186,400 | ||
| 2022-01-13 | SLATTERY JOSEPH P Director | Option exercise | +2,149 | $0.24 | $509 | 10,704 |
| 2022-01-13 | SLATTERY JOSEPH P Director | Option exercise | +3,917 | $0.24 | $928 | 14,621 |
| 2022-01-13 | SLATTERY JOSEPH P Director | Option exercise | +316 | $0.24 | $75 | 14,937 |
| 2022-01-13 | SLATTERY JOSEPH P Director | Option exercise | +316 | $0.24 | $75 | 15,253 |
| 2022-01-13 | SLATTERY JOSEPH P Director | Option exercise | +2,528 | $0.24 | $599 | 17,781 |
| 2022-01-13 | SLATTERY JOSEPH P Director | Option exercise | +189 | $0.24 | $45 | 17,970 |
| 2022-01-13 | SLATTERY JOSEPH P Director | Option exercise | +189 | $0.24 | $45 | 18,159 |
Page 15 of 22 · 422 trades